Journal
FUTURE MEDICINAL CHEMISTRY
Volume 5, Issue 3, Pages 291-300Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.13.5
Keywords
-
Categories
Funding
- CICYT [CTQ2012-30930]
- Generalitat de Catalunya [2009SGR1024]
- Institute for Research in Biomedicine Barcelona (IRB Barcelona)
- Barcelona Science Park
Ask authors/readers for more resources
Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are highly prevalent gastrointestinal disorders associated with health, economical and social problems. Recently, after a long journey of preclinical studies and clinical trials, linaclotide, a first-in-class GC-C receptor peptide agonist, has received the approval in the USA and Europe for the treatment of IBS-C and CIC. This article provides an overview of clinical, economic and biological aspects of IBS-C and CIC and covers the current and emerging therapeutic agents for treating these conditions. Particularly, the pharmacodynamic and pharmacokinetic properties of linaclotide, a small, disulfide-rich peptide, and its implications in the future of peptide drug discovery and development are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available